Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Gilead Launches Hepatitis C Treatment in China at 20% of US Price

publication date: Nov 29, 2017

Gilead Sciences priced its Sovaldi treatment for hepatitis C at $8,938 in China -- about one-fifth the current price in the US. In 2013, when the drug originally went on sale in the US, it cost $84,000 for a three-month round of treatment. Because it was 95% effective in a difficult-to-cure population, Gilead made the case that Sovaldi was worth the high cost. In most less-developed countries -- including India -- Gilead allows sales of Sovaldi at less than $400 for a three-month regimen. China is not included in that group. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.